Treatment of Korean Panax Ginseng against Cisplatin-Induced Toxicity in Rats Haematological and Histological Examination of Liver, Spleen and Kidney

Authors

  • Rekha Sathyanath
  • Hanumantha Rao Balaji Raghavendran
  • Hyeong-Keug Kim
  • Chang-Gue Son

DOI:

https://doi.org/10.37591/rrjot.v3i2.1348

Abstract

Vital goal of all anti-cancer therapies are to prevent the incidence of side effects either through more selective therapeutic methodology that target only neoplastic cells or through the use of complementary or alternative medicine. Present study investigated the effects of Panax ginseng (PG) on cisplatin-induced haematological and histopathological (liver, kidney and spleen) changes in rats. Rats were administered with PG (25, 50, 100 mg/kg) before or after an intraperitoneal injection of cisplatin (6 mg/kg). Total white blood cells (WBC), absolute neutrophil, lymphocytes and platelets on day 5 were examined. Histopathology of liver, kidney and spleen were additionally assessed. Post-treatment with PG (100 mg/kg) significantly attenuated cisplatin-induced decrease in platelets. However, cisplatin-induced changes in WBC, absolute neutrophil and lymphocytes were not significantly improved. Cisplatin-induced histopathological changes like liver sinusoidal dilatation, inflammatory infiltration, renal glomerulus damage and changes in white and red pulp of spleen were not augmented by PG. PG improves the resistance of rats against cisplatin-induced haematological or histopathological changes but toxicity was not improved in rats.

 

Keywords: Chemotherapy, cisplatin, toxicity, ginseng, haematology, histology  

 

 

Downloads

Published

2019-04-10

Issue

Vol. 3 No. 2 (2013)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.